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SbmA is an inner membrane protein of Gram-negative bacteria that is involved in the internalization of glycopeptides and pro-
karyotic and eukaryotic antimicrobial peptides, as well as of peptide nucleic acid (PNA) oligomers. The SbmA homolog BacA is
required for the development of Sinorhizobiummeliloti bacteroids within plant cells and favors chronic infections with Brucella
abortus andMycobacterium tuberculosis in mice. Here, we investigated functional features of SbmA/BacA using the proline-rich
antimicrobial peptide Bac7(1-35) as a substrate. Circular dichroism and affinity chromatography studies were used to investi-
gate the ability of SbmA to bind the peptide, and a whole-cell transport assay with fluorescently labeled peptide allowed the de-
termination of transport kinetic parameters with a calculatedKm value of 6.95 0.89Mpeptide and a Vmax of 53.91 3.17
nmol/min/mg SbmA. Use of a bacterial two-hybrid system coupled to SEC-MALLS (size exclusion chromatography coupled with
multiangle laser light scattering) analyses established that SbmA is a homodimer in the membrane, and treatment of the cells
with arsenate or ionophores indicated that the peptide transport mediated by SbmA is driven by the electrochemical gradient.
Overall, these results shed light on the SbmA-mediated internalization of peptide substrates and suggest that the transport of an
unknown substrate(s) represents the function of this protein.
SbmA is an inner membrane protein of Gram-negative bacteriafound in distantly related species, such as Enterobacteriaceae
and the alphaproteobacteria Sinorhizobium meliloti and Brucella
abortus, and required for the establishment of symbiosis with the
leguminous plant (1) or the chronic infection of the host (2, 3). It
has recently been recognized as a transporter involved in the in-
ternalization of antimicrobial peptides (AMPs) of prokaryotic (4)
and eukaryotic (5, 6) origin as well as of the glycopeptide antibi-
otic bleomycin (7–9).
SbmA is a 406-residue-long polypeptide showing seven or
eight transmembrane-spanning domains (1, 10) originally identi-
fied in Escherichia coli as a consequence of the phenotype of resis-
tance of sbmA mutants to microcin B17 (11). SbmA is involved in
the uptake of the lasso peptide microcin J25 (4) and is also re-
quired for the direct uptake of the eukaryotic proline-rich antimi-
crobial peptides Bac7 (5) and PR-39 (12). Mutants of SbmA were
recently found to be resistant to the antisense peptide phosphoro-
diamidate morpholino oligomers, suggesting that these molecules
may be transported across the plasma membrane by SbmA (13).
In addition, a role of this protein in the uptake of peptide nucleic
acid (PNA) conjugates in E. coli has been proposed, indicating
SbmA as the first protein identified to recognize PNA (14).
Although a physiological role of SbmA has not been found yet,
BacA, the ortholog of SbmA in S. meliloti, is required for the de-
velopment of S. meliloti bacteroids within plant cells (1). BacA
shows 64% sequence identity to SbmA, and it is functionally in-
terchangeable withE. coli SbmA (7). Recently, a role of BacA in the
establishment of host infections has been suggested. The protein
mediates protection of bacteria against host nodule-specific cys-
teine-rich (NCR) antimicrobial peptides, a number of host plant
peptides essential to bacteroid development (15, 16). In addition,
BacA is vital for the survival of B. abortus in the macrophages of
the host, and it favors chronic infections in BALB/c mice (2, 3). A
BacA-related protein was identified in the chronic pathogen My-
cobacterium tuberculosis (3). This protein (MtBacA) was found to
be important for the maintenance of chronic infection in a murine
infection model (3) and, recently, to be able to partially comple-
ment the symbiotic defect of an S. meliloti BacA-deficient mutant
(17). These observations suggest that the presence of SbmA/BacA
may offer advantages for the survival of the bacteria in different
environments.
Based on sequence analysis, SbmA has been proposed to be the
transmembrane domain (TMD) of an ABC transporter (10), a
widely diffused superfamily of proteins that mediate the uptake or
export of a variety of substances across cell membranes (18). ABC
transporters are dimers and have a common architecture consist-
ing of a TMD and a nucleotide binding domain (NBD), which
hydrolyzes ATP and drives the transport. Since the sbmA sequence
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does not encode an NBD (see Fig. S1 in the supplemental mate-
rial), we investigated the driving force for the eukaryotic proline-
rich antimicrobial peptide Bac7(1-35) uptake by SbmA. In addi-
tion, we looked at the oligomeric state of SbmA and measured its
binding affinity for Bac7(1-35). The results contribute to our un-
derstanding of SbmA-mediated internalization of peptides.
MATERIALS AND METHODS
Antimicrobial peptides. Bac7(1-35) and the dipyrromethene boron di-
fluoride (BODIPY [BY]) fluorescently labeled derivative Bac7(1-35)-BY
were prepared as previously described (19).
Bacterial strains, media, and growth conditions. All the bacterial
strains and plasmids used in this study are listed in Table 1. Bacterial
cultures were grown in Luria-Bertani (LB) or Mueller-Hinton (MH)
broth at 37°C under aerobic conditions with the addition, when required,
of the appropriate antibiotic at the following concentrations: 100g ml1
for ampicillin, 50g ml1for kanamycin, and 10g ml1 for tetracycline.
Cloning, expression, and purification of 6-His-tagged SbmA. The E.
coli sbmA gene was amplified from chromosomal DNA and ligated into
the expression vector pQE9 as previously described (5). The expression of
the protein was induced with 1 M isopropyl--D-1-thiogalactopyrano-
side overnight at 30°C when the bacterial suspension reached an optical
density at 600 nm (OD600) of 0.7 to 0.8. The bacterial culture was har-
vested by centrifugation for 10 min at 2,000 g; resuspended in ice-cold
lysis buffer containing 20 mM Tris-HCl, pH 7.5, 100 mM NaCl, 1% (vol/
vol) Triton X-100; and left at 4°C with stirring for 10 min. The sample was
then sonicated three times for 10 s each time with a Branson sonicator
(Branson Sonic Power S75) at 2.5 direct current (DC) amperes. After a
20-min centrifugation at 10,000 g, supernatants were applied to a nick-
el-nitrilotriacetic acid (Ni-NTA) column (Invitrogen) preequilibrated
with 5 mM imidazole in 20 mM Tris-HCl, pH 8, 1 M NaCl, 5 mM -mer-
captoethanol, 1% (vol/vol) Triton X-100. The purified protein was eluted
with 100 mM imidazole in the same buffer. The protein was further pu-
rified with gel filtration chromatography onto the Sephadex G-25 resin
(GE Healthcare) preequilibrated with 20 mM Tris-HCl, pH 7.5, 100 mM
NaCl, 0.5% (vol/vol) Triton X-100, and eluted in the same buffer. Its
concentration was determined by the bicinchoninic acid (BCA) assay kit
(Pierce) using bovine serum albumin (BSA) to obtain a standard curve.
Purification of SbmA-GFP-His8 and BacA-GFP-His8. sbmA and
bacA were cloned into the pWaldoGFPd vector. Overexpression and pu-
rification were performed as previously described (20). Both proteins
were purified in 0.03% (wt/vol) dodecyl-maltoside (DDM).
Affinity chromatography assay onto Bac7-functionalized resin. The
column preparation and the affinity chromatography were performed ac-
cording to the manufacturer’s instructions (Sulfolink resin; Pierce). The pro-
tein bound to the resin was then eluted with 12% (wt/vol) SDS, 0.4 M dithio-
threitol (DTT), 30% (vol/vol) glycerol, 0.05% (wt/vol) bromophenol blue in
0.5 M Tris-HCl, pH 6.8, and by heating at 60°C for 10 min.
Anti-SbmA antibody purification. To develop a polyclonal antibody
directed against SbmA, a peptide corresponding to the sequence starting
from position 269 was synthesized with an extra cysteine residue added at
the C-terminal end, conjugated with the sulfhydryl-reactive keyhole lim-
pet hemocyanin (KLH) (Pierce), and injected into the rabbit blood-
stream. The polyclonal antibody was then purified from the rabbit anti-
serum via affinity chromatography onto a Sulfolink resin (Pierce)
prepared according to the manufacturer’s instructions. Briefly, the anti-
serum was centrifuged at 6,000  g at 4°C, and the supernatant was fil-
tered through a 0.2-m filter and diluted with 1 volume of phosphate-
buffered saline (PBS) (1.59 mM NaH2PO4, 8.45 mM Na2HPO4, 150 mM
NaCl, pH 7.4) and incubated overnight at 4°C under constant shaking
with the functionalized Sulfolink. After repeated washing steps of the resin
with PBS, PBS HST (500 mM NaCl, 0.1% Triton X-100 in PBS), and PBS
HS (500 mM NaCl in PBS), the antibody was eluted with 200 mM glycine-
HCl, pH 2.8, and the pH of the fractions corresponding to the purified
antibody was immediately adjusted to pH 7.5 with 2 M Tris-HCl, pH 8.
The concentration of the purified antibody was measured by the BCA
assay (Pierce), and the antibody was stored at20°C with 30% glycerol.
Protein detection. Upon separation by SDS-PAGE, the proteins were
transferred to a nitrocellulose membrane using a semidry transfer appa-
ratus (Bio-Rad) at 20 V for 30 min, and the membrane was stained with
Ponceau Red. For the detection, the membrane was blocked overnight in
5% (wt/vol) milk powder in TBST solution (40 mM Tris-HCl, pH 7.5, 200
mM NaCl, 0.1% [vol/vol] Tween 20) at 4°C and then incubated for 90 min
at room temperature with the rabbit anti-SbmA antibody at a titer of
1:2,000. The membrane was then washed and incubated for 1 h at room
temperature with the goat anti-rabbit secondary antibody conjugated to
horseradish peroxidase (HRP) (GE Healthcare) at a titer of 1:2,000. The
detection of HRP was performed using the ECL Plus kit (Amersham).
In vivo bacterial two-hybrid assay. Electrocompetent E. coli BTH101
cells were cotransformed with 10 ng of plasmid pKNT25 and pUT18
carrying sbmA fused to the N terminus of the T25 subunit or to the N
terminus of the T18 subunit of the adenylate cyclase, respectively. The
cotransformants were plated on LB agar plates with 10 mg/ml X-Gal (5-
bromo-4-chloro-3-indolyl--D-galactopyranoside) and 5 M isopropyl-
-D-1-thiogalactopyranoside containing kanamycin (50 g ml1) and
TABLE 1 Bacterial strains and plasmids used in this study
Strain or plasmid Characteristics Reference or source
E. coli strains
XL1-Blue recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F= proAB lacIqZM15 Tn10 (Tetr)] Stratagene
BTH101 F cya-99 araD139 galE15 galK16 rpsL1 (Strr) hsdR2 mcrA1 mcrB1 Euromedex
BW25113 F (araD-araB)567 lacZ4787(::rrnB-3)  rph-1 (rhaD-rhaB)568 hsdR514 Genobasea
JW3710 BW25113 atpD::Kmr mutant Genobasea
DH5 supE44 lacU169(	80lacZM15) hsdR17 recA1 endA1 gyrA96 thi-1 relA1 NAc
JW0368-1 F (araD-araB)567lacZ4787(::rrnB-3) sbmA742::kan  rph-1(rhaD-rhaB)568 hsdR514 Coli Genetic Stock Center
collection
C43(DE3) Derived from C41(DE3); C41(DE3) was derived from BL21(DE3) [E. coli F ompT hsdSB(rB
 mB
) gal dcm
(DE3)] and has at least one uncharacterized mutation
35
Plasmids
pQE-9(sbmA) Expression vector, Ampr 5
pUT18C(zip) GCN4 leucine zipper cloned in pUT18C Euromedex
pKT25(zip) GCN4 leucine zipper cloned in pKT25 Euromedex
pKNT25(sbmA) sbmA cloned BamHI-EcoRI in pKNT25 Provided by G. C. Walker
pUT18(sbmA) sbmA cloned BamHI-EcoRI in pUT18 Provided by G. C. Walker
pWaldoGFPd(sbmA) Expression vector, Kanr, carrying sbmAGFP-His8 tag and a TEV
b site as fusion 20
pWaldoGFPd(bacA) Expression vector, Kanr, carrying bacAGFP-His8 tag and a TEV site as fusion 20
a Keio Collection of GenoBase (http://cgsc.biology.yale.edu/index.php).
b TEV, tobacco etch virus.
c NA, not available.
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ampicillin (100 g ml1) and left to grow at 30°C for 48 h. Clones were
considered positive when the intensity of the blue color was comparable to
that of the positive control, represented by the two leucine zipper domains
of the transcriptional factor GCN4 of Saccharomyces cerevisiae.
DNA sequencing and analysis. Sequencing of the DNA inserts on
both strands was performed at BMR Genomics (Padua, Italy) using the
specific forward (5=-GTT-CGC-CAT-TAT-GCC-GCA-TC-3=) and re-
verse (5=-GGA-TGT-GCT-GCA-AGG-CGA-TT-3=) primers. Nucleotide
sequence analyses were performed by using the EcoCYC database for the
E. coli genome (http://www.ecocyc.org/). Database similarity searches
were carried out with BLAST at the National Center for Biotechnology
Information website.
-Galactosidase activity assay. The -galactosidase activity was de-
termined on the basis of the method described by Miller (21) with few
modifications. Six hundred microliters (600l) of cells resuspended in 60
mM Na2HPO4, 40 mM NaH2PO4, 10 mM KCl, 1 mM MgSO4, 0.05 M
-mercaptoethanol, pH 7.0, was permeabilized for at least 20 min with
0.1% (wt/vol) SDS (24 l) and chloroform (48 l) and then processed as
described previously (22). The reaction was conducted at 37°C, and the
-galactosidase activity was calculated in Miller units.
In vitro cross-linking assay. Purified SbmA protein (
6 g) was
incubated with increasing concentrations of glutaraldehyde (Sigma)
(0.125, 0.25, and 0.5%, vol/vol) for 10 min at 4°C in a total reaction
volume of 20 l, then glycine was added to a final concentration of 0.125
M, and the sample was incubated for 10 min at 4°C in order to block the
reaction.
Size exclusion chromatography coupled with multiangle laser light
scattering (SEC-MALLS) analysis. The oligomeric state of detergent-pu-
rified SbmA protein was assessed using a Malvern Viscotek TDAmax
Tetra detection system, including static light scattering and UV and re-
fractive index detectors, connected downstream of a Superdex-S200 10/
300 gel filtration column equilibrated in 20 mM Tris, pH 8, 150 mM NaCl,
and 0.03% (wt/vol) DDM. The protein concentration was adjusted to 21.5
M. The data were analyzed using Omnisec (Malvern).
Flow cytometric analysis.Uptake of Bac7(1-35)-BY in E. coli cells was
determined by flow cytometry using a Cytomics FC500 instrument (Beck-
man-Coulter, Inc.) as previously described (5). Cultures of mid-log-phase
bacteria were harvested, diluted to 106 CFU ml1 in MH broth, incubated
with 0.25 M Bac7(1-35)-BY in the presence of 0.5, 1.25, and 2.5 mM
2,4-dinitrophenol (DNP) (Sigma); 0.5, 2.5, 5, and 10 mM sodium arsen-
ate (Sigma); 5M nigericin (Sigma); 5M valinomycin (Sigma), or both
at 37°C for 10 min, and analyzed immediately. All experiments were con-
ducted in triplicate, and data were expressed as mean fluorescence inten-
sity (MFI) standard deviation (SD). Data analysis was performed with
the FCS Express V3 software (De Novo Software, CA).
ATP determination. To determine the total amount of ATP in E. coli
cells, the ATP Determination kit (Invitrogen) was used. Bacterial suspen-
sions were prepared as described for the flow cytometry assays with the
addition of Bac7(1-35) in place of the fluorescent Bac7(1-35)-BY. After 10
min of incubation at 37°C with the different inhibitors, 100 l of each
bacterial suspension was transferred to a fresh 2-ml tube and 900 l of
boiling buffer containing 100 mM Tris-HCl, pH 7.8, and 4 mM EDTA was
added to each tube. The tubes were then incubated at 100°C for 2 min and
centrifuged at 9,600  g for 2 min. One hundred microliters of each
sample was assayed in triplicate with a luminometer (Hidex Chameleon).
Time course transport assay. E. coli cells, C43(DE3), harboring
SbmA-GFP-His8, were incubated in LB at 37°C with 1M Bac7(1-35)-BY
for the indicated time intervals. Transport was terminated after centrifu-
gation at 20,500 g for 1 min. Cell pellets were washed in equal volumes
of PBS buffer and resuspended in 100 l of the same buffer. Nonspecific
uptake was measured under the same conditions using JW0368-1 cells
that were sbmA deficient. All measurements were corrected for OD600.
The fluorescence counts of internalized peptide were measured using a
Spectramax spectrofluorometer at 570 nm (excitation, 544 nm). Each
experiment was performed in duplicate.
Transport kinetics. The kinetics of the Bac7(1-35)-BY transport by
SbmA were measured at various concentrations of the peptide at 37°C for
60 min; the initial peptide uptake was slow and reached maximum at 60
min. The fluorescence counts of internalized peptide were measured us-
ing a Spectramax spectrofluorometer at 570 nm (excitation, 544 nm).
Data were corrected for expressed SbmA-GFP-His8 by measuring the
green fluorescent protein (GFP) fluorescence counts at 512 nm (excita-
tion, 488 nm). Each experiment was performed in duplicate. The data
were fitted in the Michaelis-Menten equation by nonlinear regression
using GraphPad Prism.
SRCD studies. Synchrotron radiation circular dichroism (SRCD) ex-
periments were performed using a nitrogen-flushed Module B end-sta-
tion spectrophotometer at the B23 Synchrotron Radiation CD Beamline
at the Diamond Light Source, Oxfordshire, United Kingdom (23). Sam-
ples were typically prepared in 20 mM Tris-HCl, pH 7.5, and 20 mM NaCl
containing 0.03% (wt/vol) DDM. Measurements were carried out at 20°C
unless otherwise stated. For measurements in the far-UV range (180 to
260 nm), the concentration of SbmA and BacA employed was in the range
of 10 to 25M. Aliquots of Bac7(1-35) stock solution in water were added
to SbmA and BacA stock solutions of 10 and 24 M, respectively, for the
titrations at various molar stoichiometries. Using sample volumes of 30
l, four scans were acquired using an integration time of 1 s, a path length
of 0.02 cm, and a slit width of 0.5 mm equivalent to a 1.2-nm bandwidth.
For thermal stability, both SbmA and BacA were incubated in the presence
and absence of 5-fold Bac7(1-35) at 5°C and spectra were measured every
5°C over a temperature range between 5°C and 95°C with 5 min of equil-
ibration time for each temperature. Reversibility was monitored by mea-
suring the spectrum at 5°C after cooling from 95°C with 30 min of incu-
bation time. For measurements in the near-UV region (250 to 340 nm),
experiments were conducted in the same buffer using 100 l of sample
with concentration ranging from 10 to 25 M at 20°C using a low-vol-
ume, small-aperture (2-mm), 1-cm-path-length cell. The spectra were
reported as differential absorption A, which is a differential absorption
of left and right circular polarized light. The A values at 223 nm were
plotted against concentrations of Bac7(1-35) in the mixture. For one
binding site approximation, the dissociation constant Kd was determined
using the nonlinear regression analysis as reported by Siligardi et al. (24).
Statistical analysis. The significance of differences among bacterial
strains treated with increasing concentrations of sodium arsenate, DNP,
nigericin, and/or valinomycin was assessed using GraphPad Prism by the
Student-Newman-Keuls multiple comparison test and analysis of vari-
ance (ANOVA).
RESULTS
The SbmA-mediated transport of Bac7 is proton driven rather
than ATP driven. From the sequence analysis, sbmA does not
encode an NBD (see Fig. S1 in the supplemental material). To
determine the driving force of the transport, we first measured the
uptake of Bac7(1-35)-BY in the presence of increasing concentra-
tions of DNP or sodium arsenate. DNP is an ionophore which
moves protons across the inner membrane and affects both the
pH gradient and the membrane potential, while sodium arsenate
inhibits production of ATP via substrate-level phosphorylation
(25).
To correlate the uptake of Bac7(1-35)-BY with the ATP con-
centration of the cells, we measured the ATP level in bacterial cells
treated with DNP or sodium arsenate. The uptake assay and the
measurement of the ATP concentration were performed in the E.
coli strain JW3710, carrying a deletion in the gene atpD encoding
the -subunit of the ATP synthase (Table 1). In this strain, ATP is
produced exclusively by substrate phosphorylation, and there-
fore, the DNP affects only the proton gradient and not the ATP
content, since the ATP synthase is impaired. By using this mutant,
the effect of the DNP on the proton gradient can be evaluated
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separately from its indirect effect on ATP synthesis. On the other
hand, the sodium arsenate should dramatically reduce the amount
of ATP in the cell acting on substrate phosphorylation.
We showed that treatment with increasing concentrations of
sodium arsenate did not inhibit the uptake of Bac7(1-35)-BY by
the cells, despite a significant reduction in ATP cell content (Fig.
1A). In contrast, the treatment of the bacteria with increasing
concentrations of DNP caused a significant decrease in the
amount of internalized peptide, although the ATP content still
remained high (Fig. 1B). The low reduction of the ATP content,
observed after treatment of the cells with DNP, is scarcely concen-
tration dependent and might be due to an attempt of the cell to
pump out protons consuming ATP in order to counteract the
DNP-mediated proton flow across the membrane. Taken to-
gether, these results highlight the predominant effect of the un-
coupler on the uptake and confirm that this effect is not directly
related to the ATP content.
To assess which component of the proton motive force is nec-
essary for the transport of Bac7(1-35)-BY, we evaluated its uptake
in the presence of different specific ionophores (Fig. 1C). Nigeri-
cin mediates the antiport of H and K down their concentration
gradients and thereby dissipates the transmembrane proton gra-
dient (pH,) leaving unaltered the transmembrane potential. In
contrast, valinomycin mediates the uptake of K in the cell, selec-
tively dissipating the transmembrane potential (). The treat-
ment of the cells with nigericin or valinomycin reduced the
amount of internalized peptide, but the highest reduction of in-
ternalized peptide was observed when both ionophores were pres-
ent. These results indicate that both components of the electro-
chemical transmembrane gradient are required for transport.
Whole-cell transport assays. The SbmA transport kinetics
were measured by using E. coli whole-cell transport assays. A time
course uptake assay in the presence of Bac7(1-35)-BY is shown in
Fig. 2A. Cells expressing endogenous or recombinant SbmA
transport larger amounts of Bac7 than do cells that are sbmA de-
ficient, in agreement with previous studies (5). The initial peptide
uptake was slow and reached maximum at 60 min. Cells express-
ing recombinant SbmA-GFP were used to calculate SbmA-depen-
dent transport kinetics and displayed a Km of 6.95 0.89M and
a Vmax of 53.91 3.17 nmol/min/mg SbmA (Fig. 2B).
SbmA binds Bac7 in vitro. A previous study has shown that
SbmA is necessary for the transport of proline-rich AMPs (5). To
establish whether SbmA directly binds Bac7, we analyzed the abil-
ity of the two molecules to form a complex in vitro. Purified SbmA
was used in affinity chromatography on a Bac7(1-35)-functional-
ized resin. Two forms of recombinant SbmA were produced: one
obtained after cleavage of the GFP moiety from the SbmA-GFP
fusion protein and the other fused with a His tag. Both recombi-
nant proteins were used to test the binding to Bac7 and gave sim-
ilar results. Figure 3 shows that the His-tagged SbmA is retained by
the Bac7(1-35) resin, even though with low efficiency.
Studies of binding of Bac7 to SbmA and to BacA by CD spec-
troscopy. The CD spectroscopy studies provided further evidence
that SbmA and BacA can interact with Bac7 in vitro. Bac7(1-35)
was titrated at various molar stoichiometries to SbmA and BacA,
and CD spectra in the far-UV region (180 to 260 nm) and the
near-UV region (250 to 330 nm) were recorded. In the far-UV
region, significant changes in the secondary structure of the mix-
ture were observed when Bac7(1-35) was added to SbmA (Fig. 4A;
see also Fig. S2A in the supplemental material) and BacA (Fig. 4B;
see also Fig. S3A in the supplemental material), indicating inter-
action of SbmA and BacA with Bac7 accompanied by structural
changes for either SbmA/BacA, Bac7, or both (Table 2). In the
near-UV region, characteristic of the local tertiary structure of
aromatic side chain residues, there were not significant changes,
suggesting that no aromatic residues are involved in the interface
between Bac7(1-35) and SbmA/BacA (see Fig. S2B and S3B). The
results showed that Bac7(1-35) has a high binding affinity to both
SbmA and BacA with aKd of 0.3M (Fig. 4). Temperature studies
FIG 1 Effect of different inhibitors on the uptake of Bac7(1-35)-BY and on the
ATP content of E. coli cells. Black bars represent the uptake of Bac7(1-35)-BY
in E. coli JW3710 (atpD) cells measured as medium fluorescence intensity
(M.F.I.) in the presence of increasing concentrations of sodium arsenate (A),
DNP (B), and valinomycin and/or nigericin (C). Gray bars represent the ATP
content of the cells measured as luminescence produced by the firefly lucifer-
ase reaction. The level of luminescence is expressed as a percentage of lumi-
nescence after treatment with the different inhibitors with respect to the con-
trol, which represents the 100% value. *, P  0.05 versus untreated; **, P 
0.01; ***, P 0.005; #, P 0.001 versus untreated; ##, P 0.0001.
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were also carried out for SbmA and the mixture with Bac7 (see Fig.
S2C). No significant differences between the melting temperature
Tm of SbmA and that of the mixture with Bac7 (Tm 55°C) were
observed (see Fig. S2D). It is interesting that the conformational
changes were not accompanied by differences in thermal stability
for either SbmA or BacA (see Fig. S2D, S3C, and S3D); this could
possibly be due to rearrangement of the secondary structure of the
proteins, with SbmA having a loss of alpha-helix content (11%)
FIG 2 SbmA transport kinetics in whole E. coli cells. (A) Time-dependent inter-
nalization of Bac7(1-35)-BY. Cells that are sbmA deficient show a low level of
nonspecific uptake (filled circles). In the presence of endogenous SbmA, the up-
take increases by 6-fold (filled diamonds). Cells that are carrying the expression
vector without induction show uptake levels similar to those of nontransformed
cells (filled squares). Cells that are expressing recombinant SbmA-GFP-His8 show
a 1.8-fold increase relative to the wild-type cells (empty circles). (B) Michaelis-
Menten transport kinetics of SbmA-mediated Bac7(1-35)-BY uptake.
FIG 3 In vitro assay of the binding of SbmA to Bac7. (A) SDS-PAGE analysis of the
6-His-taggedSbmAproteinboundbytheBac7(1-35)-functionalizedresin.Bindingof
the native SbmA protein to the unfunctionalized resin (Cys-resin) has been used as a
negative control. I, input SbmA; B, bound SbmA; UB, unbound SbmA. (B) Western
blot analysis of the samples analyzed by SDS-PAGE using an anti-SbmA antibody.
FIG 4 Effect of Bac7 on the secondary structure of SbmA and BacA. Far-UV
spectra of SbmA (A) and BacA (B) in the presence of increasing amounts of Bac7.
The spectra were reported as differential absorption A, which is a differential
absorption of left and right circular polarized light. The insets show theA values
at 223 nm plotted against concentrations of Bac7(1-35) in the mixture.
TABLE 2 Determination of secondary structure composition of SbmA






H1, alpha-helix 0.41 0.32 0.41 0.46
H2, distorted alpha-helix 0.19 0.17 0.19 0.19
S1, -strand 0.04 0.09 0.06 0.03
S2, distorted -strand 0.04 0.04 0.03 0.02
T, turn 0.12 0.10 0.12 0.10
U, unordered 0.21 0.28 0.20 0.20
Spectral fit SD 0.06 0.04 0.06 0.04
a CONTIN algorithms (36–38). SMP50, data set of 37 soluble proteins and 13
membrane proteins using a spectral range of 185 to 240 nm.
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but compensated by an increase in beta-sheet (5%) upon bind-
ing of Bac7 to SbmA, while in the case of BacA, a loss of beta-
sheet (3%) is compensated by an increase in alpha-helix (5%)
in the presence of Bac7, which resulted in no change of the Tm
observed.
SbmA is able to form dimers. To study the oligomeric state of
SbmA, we performed a bacterial two-hybrid assay expressing
SbmA fused to the T18 or T25 subunit of the adenylate cyclase of
Bordetella pertussis (26). Cotransformation of E. coliBTH101 with
both the plasmids carrying the fusion proteins resulted in func-
tional complementation between the two halves of the adenylate
cyclase, indicating that two SbmA monomers are able to interact
(Fig. 5A). We also showed that the strength of this interaction is
comparable to that of the positive control (Fig. 5B). An in vitro
(Fig. 6A) cross-linking assay with the purified recombinant His-
tagged SbmA in the presence of increasing amounts of glutaralde-
hyde showed that this protein forms dimers.
The oligomeric state of detergent-purified SbmA was also stud-
ied using size exclusion chromatography coupled with multiangle
laser light scattering (SEC-MALLS). The predicted molecular
mass of SbmA from the primary sequence is 46.46 kDa. The
DDM-solubilized and purified SbmA is monodisperse in solution
as evaluated from the 280-nm detector. The molecular mass of the
SbmA-DDM complex cannot be determined accurately from the
280-nm detector since we cannot calculate how much detergent is
bound to SbmA. Therefore, the molecular mass was calculated
from the refractive index detector (Fig. 6B).The elution peak was
FIG 5 In vivo dimerization of SbmA. (A) Bacterial two-hybrid assay. E. coli
BTH101 cells were cotransformed with pUT18C-zip and pKT25-zip vectors as
a positive control (1), pKNT25-sbma and empty pUT18 (2), and pUT18-sbma
and pKNT25-sbma (3). (B) -Galactosidase assay to measure the enzymatic
activity expressed as Miller units (M.U.). Bar numbers correspond to plate
numbers in panel A. Results are the means of four independent experiments.
FIG 6 Invitrodimerization of SbmA. (A) Western blot analysis of the recombinant His-tagged SbmA incubated in the presence of increasing amounts of glutaraldehyde;
the dimer is indicated by the arrow. At a high percentage of cross-linking agent (0.5%, vol/vol), superaggregated forms of the protein become visible. (B) SEC-MALLS
analysis of SbmA in solution. The chromatogram shows the detector readings of UV280 (solid line) and refractive index (dotted line; scale on right-hand y axis). The thick
black line indicates the calculated molecular mass of the eluted protein throughout the peak (scale on left-hand y axis). Data were analyzed as in reference 27. The average
molecular mass of the SbmA-DDM complex was calculated to be 223 kDa, across the refractive index detector elution peak (dotted line) (27). The average molecular mass
of the SbmA assembly is 89.2 kDa. Solid and dashed arrows indicate SbmA-DDM complex and free DDM micelle, respectively.
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calculated to be 223 kDa, corresponding to the SbmA-DDM com-
plex. A smaller peak at 78.5 kDa that appears only at the refractive
index detector corresponds to empty detergent micelles (Fig. 6B).
The average molecular mass of SbmA from the elution peak, ex-
cluding the contribution of the detergent micelle (27), was deter-
mined to be 89.2 kDa, which confirms that SbmA exists as a dimer
in the DDM solution.
DISCUSSION
A number of reports have stressed the importance of the E. coli
inner membrane protein SbmA in the bacterial susceptibility to
some antibiotics and antibacterial peptides. However, a role for
SbmA in the uptake of AMPs has been proposed only in the past 5
years (5). New insights in SbmA function came from the observa-
tion that BacA, the SbmA homolog in S.meliloti, is essential for the
survival of the bacteria in the plant symbiosome and the resistance
to NCR peptides released by the plant (15). In this study, we
showed for the first time that (i) the energization process of the
SbmA-mediated transport is based on the electrochemical trans-
membrane gradient rather than on ATP hydrolysis, (ii) in vitro
Bac7(1-35) binds to SbmA and its homolog BacA with high affin-
ity, (iii) Bac7(1-35) is efficiently transported across the membrane
by SbmA, and (iv) SbmA is homodimeric in vitro and in vivo.
SbmA as well as BacA and BacA-related proteins has been orig-
inally proposed to be the TMD of an ABC transporter on the basis
of its sequence similarity (10). However, the alignment of E. coli
SbmA and S. meliloti BacA with BacA-related proteins that carry
an NBD in their sequence showed low sequence identity at the
TMD region (
20%) (see Fig. S1 in the supplemental material).
In addition, SbmA and its homolog BacA do not have any motif
with ATPase activity in their sequence. These preliminary obser-
vations prompted us to evaluate whether ATP hydrolysis was re-
quired to translocate the proline-rich fragment Bac7(1-35) pep-
tide across the inner membrane. A preliminary screen via a
bacterial two-hybrid system to look for a possible orphan ATP
binding domain and pulldown assays failed to identify any inter-
acting NBD partners specific for SbmA (data not shown).
We observed that a major reduction of the uptake of Bac7(1-
35) could be obtained after treatment of the bacterial cells with the
uncoupler DNP, without a consistent decrease in ATP level, or
with ionophores that disrupt both the chemical and electrical
components of the proton motive force. These results indicate
that the uptake of Bac7(1-35) requires the presence of a trans-
membrane electrochemical gradient rather than ATP hydrolysis
to be fully accomplished.
SbmA has the notable feature of internalizing structurally un-
related bacterial peptides, including MccB17 (11), MccJ25 (4),
and the nonpeptide antibiotic bleomycin (9), in addition to the
eukaryotic AMP Bac7(1-35). MccJ25 is a 21-amino-acid post-
translationally modified peptide that adopts a lasso structure,
whereas MccB17 and bleomycin contain thiazole heterocycles
(MccB17 also contains oxazoles). Moreover, recent findings sug-
gest the involvement of SbmA also in the internalization of anti-
sense peptide phosphorodiamidate morpholino oligomers and
PNAs (13, 14), expanding the spectrum of substrates transported
by this protein. More importantly, a high level of promiscuity to
export structurally unrelated peptides is a feature typical of mul-
tidrug transporters (28, 29). Interestingly, when the multidrug
ABC transporter LmrA from Lactococcus lactis is deprived of its
NBD, it acts as a secondary-active multidrug uptake system ener-
gized by the proton gradient (30), which suggests that the evolu-
tionary precursor of LmrA was a secondary-active transporter that
acquired an NBD to become a multidrug efflux system. Another
example of switching mode of energy coupling to transport is the
E. coli ArsAB transporter responsible for arsenite efflux. In vivo
transport studies suggest that the ArsB protein mediates the elec-
trochemical energy-dependent arsenite efflux in the absence of the
NBD protein ArsA, while the ArsAB complex catalyzes ATP-de-
pendent transport (31). Across the bacterial genomes, some ars
operons have both arsA and arsB genes and thus encode ATP-
dependent pumps, while others have only the arsB gene and en-
code secondary systems, thus suggesting that the acquisition of a
gene for a catalytic subunit might be a recent evolutionary event.
This observation suggests that SbmA may have the characteristics
of an evolutionary ancestor of a multidrug ABC transporter with
“import” direction of transport in the absence of an NBD. Inter-
estingly, in E. coli there is a gene coding for a putative longer
SbmA-like protein of unknown function, YddA, carrying an ad-
ditional C-terminal domain with an ATPase moiety, and this pro-
tein represents a full ABC transporter. The BacA-related protein
of M. tuberculosis is another example of a complete ABC trans-
porter. The MtBacA protein is 22% identical to S. meliloti BacA and
contains a fused putative ATPase domain at the C terminus of the
protein. It mediates peptide uptake of the truncated bovine Bac7(1-
16) in a process requiring a functional ATPase domain (17).
The possibility that SbmA may be part of a dimer or a complex
was reported to explain the dominant negative character of some
BacA (10) and SbmA (5) mutations. Two-hybrid screening, cross-
linking assay, and size exclusion chromatography strongly indi-
cated that SbmA forms homodimers both in vitro and in the bac-
terial membrane and that this is very likely the functional form of
this protein. In addition, we obtained some insights on the num-
ber of transmembrane spans and of its N and C terminus localiza-
tion. Given the constraints of the two-hybrid system, which can
functionally reconstitute the two subunits of the adenylate cyclase
only on the cytoplasmic side of the bacterial membrane, in this
study we provide indirect evidence on the localization of the C
terminus of SbmA inside the bacterial cell, as the two subunits
fused to the C termini gave a detectable interaction. In addition,
when the T25 and T18 subunits were cloned at the N terminus of
SbmA, the two monomers still continued to interact, suggesting
that their N terminus ends are also on the cytoplasmic side, as
detailed in the accompanying article by Corbalan et al. (32). These
data are in agreement with a previous study on the global topology
of the E. coli inner membrane proteome (33), indicating that the C
terminus of this protein is in the cytoplasm. Taken together, these
data suggest that SbmA is an eight-transmembrane-span protein
with both ends in the cytoplasm.
A role of SbmA in the transport of Bac7 was already proposed
(5). In the present work, we calculated the Km and maximum rate
of transport for the Bac7(1-35) by SbmA. Both parameters are in
the same concentration range of other peptide transporters, such
as the oligopeptide transport system Opp of L. lactis (34). The Opp
has a transport affinity in the range of 700 M for tetrapeptides,
and the affinity increases to 8.8 M for 11-amino-acid-long pep-
tides. SbmA also appears to have high affinity, with a Km of 6.95
M for the 35-amino-acid-long peptide Bac7(1-35).
The CD spectroscopy studies showed that binding of Bac7(1-
35) to SbmA and also to BacA produced some significant changes
in the secondary structure of one of the partners or both of them.
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The Bac7(1-35) did not show any structural features in the CD
experiments, and the SbmA was mostly helical. The protein sec-
ondary structure estimation of SbmA showed a more pronounced
unfolding with a loss of 11% of alpha-helix and a significant in-
crease in disorder content of the protein upon binding to Bac7
(using the CONTIN algorithm) (Table 2). BacA, however, showed
a mixture of a loss of 4% in -strand and turn and a gain of 5%
alpha-helix upon binding to Bac7. This contributed to the overall
small change in the conformation upon binding to Bac7. In addition,
the binding of SbmA and its homologous protein BacA to the antibi-
otic bleomycin did not show any changes in the secondary structure
(data not shown). This not only supports the binding of structurally
unrelated peptides to BacA and SbmA but suggests also that the Bac7
binding process involves secondary structural changes.
It is known that BacA is essential for the persistence of bacteria
within plant and mammalian hosts (1), whereas the physiological
function of SbmA is still unknown. Our data suggest that this
protein may be involved in the uptake of certain unknown pep-
tides, triggering a specialized function. Since SbmA is widespread
in enteric bacteria, its function may be linked to a specific ecolog-
ical niche represented by the gut of the host and it may contribute
to the persistence of these bacteria within the intestine.
In conclusion, in this work we showed that SbmA is a second-
ary active transporter energized by the transmembrane electro-
chemical gradient and we shed light on the SbmA-mediated inter-
nalization of peptides, showing that the eukaryotic peptide
Bac7(1-35) is capable of directly binding to SbmA with high affin-
ity, causing conformational changes of the transporter. The results
from this study are useful for designing novel peptides and anti-
biotic peptides able to penetrate efficiently into SbmA/BacA-car-
rying bacteria.
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